Beauty Health (SKIN)
(Delayed Data from NSDQ)
$1.60 USD
-0.06 (-3.61%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $1.60 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.60 USD
-0.06 (-3.61%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $1.60 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Zacks News
Organon (OGN) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Organon (OGN) delivered earnings and revenue surprises of 7.76% and 5.40%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
CoDiagnostics, Inc. (CODX) Surges 5.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
CoDiagnostics, Inc. (CODX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
TRxADE (MEDS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
TRxADE (MEDS) delivered earnings and revenue surprises of -44.44% and 13.07%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
The Beauty Health Company (SKIN) Stock Jumps 5.6%: Will It Continue to Soar?
by Zacks Equity Research
The Beauty Health Company (SKIN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Wall Street Analysts See a 69% Upside in The Beauty Health Company (SKIN): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 69.3% upside potential for The Beauty Health Company (SKIN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Can The Beauty Health Company (SKIN) Climb 57% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for The Beauty Health Company (SKIN) points to a 56.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Why Beauty Health (SKIN) Might Surprise This Earnings Season
by Zacks Equity Research
Beauty Health (SKIN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.